"10.1371_journal.pone.0076158","plos one","2013-10-02T00:00:00Z","Sujal M Parikh; Ekwaro A Obuku; Sarah A Walker; Aggrey S Semeere; Brandon J Auerbach; James G Hakim; Harriet Mayanja-Kizza; Peter N Mugyenyi; Robert A Salata; Cissy M Kityo; on behalf of the DART Trial Team","Joint Clinical Research, Centre, Kampala, Uganda; Medical Research Council Clinical Trials Unit, London, United Kingdom; University of Michigan Medical School, Ann Arbor, Michigan, United States of America; Case Western Reserve University, Department of Medicine, Cleveland, Ohio, United States of America; Makerere University College of Health Sciences, Department of Medicine, Kampala, Uganda; Makerere University College of Health Sciences, Infectious Diseases Institute, Kampala, Uganda; Harvard University, Harvard Medical School, Boston, Massachusetts, United States of America; University of Zimbabwe Clinical Research Centre, College of Health Sciences, Harare, Zimbabwe","Conceived and designed the experiments: SMP HMK ASS EAO BJA PNM RAS CKM. Performed the experiments: EAO SAW HMK ASS BJA PNM RAS CKM. Analyzed the data: EAO SAW. Contributed reagents/materials/analysis tools: EAO SAW SMP HMK ASS BJA JH PNM RAS CKM. Wrote the manuscript: EAO SAW SMP HMK ASS BJA JH PNM RAS CKM.","Viiv Healthcare/GlaxoSmithKline, Gilead and Boehringer-Ingelheim donated first-line drugs for DART, and Abbott provided Kaletra/Aluvia as part of the second-line regimen for DART. There are no patents, products in development or marketed products to declare. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials.","2013","10","Sujal M Parikh","SMP",11,TRUE,8,8,2,10,TRUE,FALSE,TRUE,2,"10;11",TRUE
